In a report released on April 29, Conor McNamara from RBC Capital maintained a Buy rating on SOPHiA GENETICS (SOPH – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $5.10.
According to TipRanks, McNamara is an analyst with an average return of -11.4% and a 32.63% success rate. McNamara covers the Healthcare sector, focusing on stocks such as QuidelOrtho, Bio-Rad Laboratories, and Maravai Lifesciences Holdings.
SOPHiA GENETICS has an analyst consensus of Strong Buy, with a price target consensus of $8.00.
SOPH market cap is currently $328.5M and has a P/E ratio of -4.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SOPHiA GENETICS (SOPH) Company Description:
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities.
Read More on SOPH:
- SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
- SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
- Sophia Genetics reports Syndicate Bio as first liquid biopsy customer in Africa
- Sophia Genetics, Strand Life Sciences announce new strategic partnership
- Sophia Genetics announces first HRD customer in Canada
